Eli Lilly Moves to Transform Sleep Disorder Treatment with Major Centessa Acquisition

Acquisition signals a major push to develop next-generation treatments for sleep disorders and neurological conditions

In a significant move within the pharmaceutical industry, Eli Lilly has announced plans to acquire Centessa Pharmaceuticals, a biotech firm focused on developing innovative treatments for sleep-related disorders. The deal, valued at approximately $6.3 billion upfront, could rise further with milestone-based payments.

Centessa has been gaining attention for its cutting-edge research targeting the brain’s sleep-wake system. Its lead drug candidate, designed to treat excessive daytime sleepiness, has shown promising results in early clinical trials for conditions like narcolepsy and idiopathic hypersomnia. These disorders affect thousands of people globally, often disrupting daily life and productivity.

By bringing Centessa under its umbrella, Lilly aims to strengthen its neuroscience portfolio and expand into sleep medicine, an area with growing demand and limited effective treatments. The acquisition also allows Lilly to leverage its global research, regulatory, and commercial capabilities to accelerate drug development.

Carole Ho, Executive Vice President and President of Lilly Neuroscience, highlighted the importance of the deal, stating that targeting the brain’s sleep-wake system presents “one of the most compelling opportunities in neuroscience.”

As reported by CIO Bulletin, the transaction reflects a broader trend in the pharmaceutical sector, where large companies are investing heavily in innovative biotech to address unmet medical needs. The deal is expected to close in the third quarter of 2026, pending regulatory and shareholder approvals. If successful, this acquisition could pave the way for more effective treatments, offering hope to patients struggling with chronic sleep disorders worldwide.